<antigenSupportingData>
<immunity>
</immunity>
<contraindications>
<vaccineGroup>
<contraindication>
<observationCode>080</observationCode>
<observationTitle>Adverse reaction to vaccine component</observationTitle>
<contraindicationText>Do not vaccinate if the patient has had an adverse reaction to a vaccine component.</contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
<contraindication>
<observationCode>119</observationCode>
<observationTitle>Severe allergic reaction after previous dose of cholera</observationTitle>
<contraindicationText>Do not vaccinate if the patient has had a severe allergic reaction after a previous dose of cholera vaccine.</contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
</vaccineGroup>
</contraindications>
<series>
<seriesName>Cholera 1-dose series</seriesName>
<targetDisease>Cholera</targetDisease>
<vaccineGroup>Cholera </vaccineGroup>
<seriesAdminGuidance>The Vaxchora package insert states that CVD 103-HgR should not be given to patients who have received oral or parenteral antibiotics in the preceding 14 days, because antibiotics might have activity against the vaccine strain. </seriesAdminGuidance>
<seriesAdminGuidance>Non-U.S. vaccines (WC-rBS and BivWC) would count as valid only if there is documentation that a complete series with the appropriate dosing has been given.</seriesAdminGuidance>
<seriesAdminGuidance>No data exist on use of the currently available lyophilized CVD 103-HgR formulation in immunocompromised populations.</seriesAdminGuidance>
<seriesType>Risk</seriesType>
<equivalentSeriesGroups/>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>No</productPath>
<seriesGroupName>Increased Risk</seriesGroupName>
<seriesGroup>1</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>1</seriesPreference>
<minAgeToStart>2 years</minAgeToStart>
<maxAgeToStart>65 years</maxAgeToStart>
</selectSeries>
<indication>
<observationCode>
<text>Travel to an area of active cholera transmission</text>
<code>008</code>
</observationCode>
<description>Administer to travelers from the United States traveling to an area of active cholera transmission.</description>
<beginAge>2 years</beginAge>
<endAge>65 years</endAge>
<guidance/>
</indication>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>2 years - 4 days</absMinAge>
<minAge>2 years</minAge>
<earliestRecAge>2 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval/>
<allowableInterval/>
<preferableVaccine>
<vaccineType>cholera, live attenuated</vaccineType>
<cvx>174</cvx>
<beginAge>6 years</beginAge>
<endAge>65 years</endAge>
<tradeName/>
<mvx/>
<volume>100</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>cholera, live attenuated</vaccineType>
<cvx>174</cvx>
<beginAge>2 years</beginAge>
<endAge>6 years</endAge>
<tradeName/>
<mvx/>
<volume>50</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>cholera, live attenuated</vaccineType>
<cvx>174</cvx>
<beginAge>2 years - 4 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
</antigenSupportingData>
